Fosun Pharmaceutical (02196) Announces Poll Results of 2026 EGM and Class Meetings

Bulletin Express02-27

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) disclosed the voting results of its 2026 first extraordinary general meeting (EGM), alongside its 2026 first A Shareholders’ Class Meeting and 2026 first H Shareholders’ Class Meeting, all held on 27 February 2026.

The primary focus of these meetings was to consider special resolutions related to spinning off Fosun Adgenvax for a listing on the main board of the Hong Kong Stock Exchange. According to disclosed results, all resolutions presented at the EGM were approved. The H Shareholders’ Class Meeting passed the relevant resolution on providing assured entitlements, but the same resolution did not gain sufficient support at the A Shareholders’ Class Meeting. Consequently, assured entitlements will not be provided to any shareholders under the proposed spin-off. The announcement confirms that failure to pass the resolution in the A Shareholders’ Class Meeting does not affect proceeding with the spin-off plan.

The official poll tallies and legal opinion issued by the company’s PRC legal advisers confirm the legality and validity of all meeting procedures and voting outcomes. The announcement underscores that the proposed spin-off will continue without offering assured entitlements to any class of shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141383303?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141383303","market":"hk","top_or_hot":-1,"title":"Fosun Pharmaceutical (02196) Announces Poll Results of 2026 EGM and Class Meetings","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) disclosed the voting results of its 2026 first extraordinary general meeting (EGM), alongside its 2026 first A Shareholders’ Class Meeting and 2026 first H Shareholders’ Class Meeting, all held on 27 February 2026.</p>\n<p>The primary focus of these meetings was to consider special resolutions related to spinning off Fosun Adgenvax for a listing on the main board of the Hong Kong Stock Exchange. According to disclosed results, all resolutions presented at the EGM were approved. The H Shareholders’ Class Meeting passed the relevant resolution on providing assured entitlements, but the same resolution did not gain sufficient support at the A Shareholders’ Class Meeting. Consequently, assured entitlements will not be provided to any shareholders under the proposed spin-off. The announcement confirms that failure to pass the resolution in the A Shareholders’ Class Meeting does not affect proceeding with the spin-off plan.</p>\n<p>The official poll tallies and legal opinion issued by the company’s PRC legal advisers confirm the legality and validity of all meeting procedures and voting outcomes. The announcement underscores that the proposed spin-off will continue without offering assured entitlements to any class of shareholders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharmaceutical (02196) Announces Poll Results of 2026 EGM and Class Meetings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharmaceutical (02196) Announces Poll Results of 2026 EGM and Class Meetings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-27 22:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) disclosed the voting results of its 2026 first extraordinary general meeting (EGM), alongside its 2026 first A Shareholders’ Class Meeting and 2026 first H Shareholders’ Class Meeting, all held on 27 February 2026.</p>\n<p>The primary focus of these meetings was to consider special resolutions related to spinning off Fosun Adgenvax for a listing on the main board of the Hong Kong Stock Exchange. According to disclosed results, all resolutions presented at the EGM were approved. The H Shareholders’ Class Meeting passed the relevant resolution on providing assured entitlements, but the same resolution did not gain sufficient support at the A Shareholders’ Class Meeting. Consequently, assured entitlements will not be provided to any shareholders under the proposed spin-off. The announcement confirms that failure to pass the resolution in the A Shareholders’ Class Meeting does not affect proceeding with the spin-off plan.</p>\n<p>The official poll tallies and legal opinion issued by the company’s PRC legal advisers confirm the legality and validity of all meeting procedures and voting outcomes. The announcement underscores that the proposed spin-off will continue without offering assured entitlements to any class of shareholders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1141383303","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141383303","pubTimestamp":1772202150,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) disclosed the voting results of its 2026 first extraordinary general meeting (EGM), alongside its 2026 first A Shareholders’ Class Meeting and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(02196)公布2026年临时股东大会及类别会议投票表决结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) disclosed the voting results of its 2026 first extraordinary general meeting (EGM), alongside its 2026 first A Shareholders’ Class Meeting and 2026 first H Shareholders’ Class Meeting, all held on 27 February 2026.\nThe primary focus of these meetings was to consider special resolutions related to spinning off Fosun Adgenvax for a listing on the main board of the Hong Kong Stock Exchange. According to disclosed results, all resolutions presented at the EGM were approved. The H Shareholders’ Class Meeting passed the relevant resolution on providing assured entitlements, but the same resolution did not gain sufficient support at the A Shareholders’ Class Meeting. Consequently, assured entitlements will not be provided to any shareholders under the proposed spin-off. The announcement confirms that failure to pass the resolution in the A Shareholders’ Class Meeting does not affect proceeding with the spin-off plan.\nThe official poll tallies and legal opinion issued by the company’s PRC legal advisers confirm the legality and validity of all meeting procedures and voting outcomes. The announcement underscores that the proposed spin-off will continue without offering assured entitlements to any class of shareholders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141383303","isCrawlerRequest":true}